Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 4/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215604 | 1.00 | MAOB (0.53) | MAOBAKR1C3AKR1C2TRPA1TRPM8 | |
| SCHEMBL4217693 | 0.91 | TRPA1 (0.50) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL4217699 | 0.91 | TRPA1 (0.50) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL4223477 | 0.87 | SIRT2 (0.53) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL4223479 | 0.87 | SIRT2 (0.53) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL4225636 | 0.86 | MMP1 (0.50) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL4225643 | 0.86 | MMP1 (0.50) | AKR1C3AKR1C2TRPA1GRIK1SNCA | |
| SCHEMBL30294413 | 0.86 | MPO (0.58) | AKR1C3AKR1C2MPOGRIK1TAS2R14 | |
| SCHEMBL22852832 | 0.86 | MPO (0.58) | AKR1C3AKR1C2MPOGRIK1TAS2R14 | |
| SCHEMBL13877522 | 0.85 | AKR1C3 (0.55) | AKR1C3AKR1C2TRPA1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | MAOB 2181/4885AKR1C3 105/4885AKR1C2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.